Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

146.12
+2.681.87%
Post-market: 146.120.00000.00%19:56 EDT
Volume:5.38M
Turnover:787.47M
Market Cap:181.29B
PE:-55.88
High:147.91
Open:144.52
Low:143.50
Close:143.44
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:1.00
T/O Rate:0.43%
Dividend:3.22
Dividend Rate:2.20%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.33
PE(LYR):21.55

Loading ...

Dow Jones Top Company Headlines at 7 PM ET: SpaceX Revenue Could Reach $1 Trillion, Elon Musk Says | Paramount's ...

Dow Jones
·
Aug 05

Gilead Forecasts FY26 Yeztugo Revenue at About $1 Billion

Reuters
·
Aug 05

Gilead CEO Daniel O’Day Sells 15,000 Common Shares Worth $1.96 Million

Reuters
·
Aug 05

Gilead Says Q2 2026 Revenue Growth is Driven by Biktarvy, Descovy and Yeztugo Demand, Pricing Gains

Reuters
·
Aug 05

Gilead Sciences Posts Net Loss as R&D Costs from Acquisitions Weigh on HIV Drug Revenue Growth

Deep News
·
Aug 05

Gilead Sciences, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Gilead Exec Says Saw a Softer Hiv Treatment Market in Q2 as People Fell Out of Insurance Plans Due to Eliminated Aca Tax Subsidies - Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Exec Says Raising Full Year Hiv Growth Expectations to 9%-10% Year-over-Year from Prior Guidance of 8% Growth - Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Exec Says Launch Preparations Fully Underway for Anito-Cel Cell Therapy, with Five Months to Go Until FDA Pdufa Date - Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Exec Says Do not Currently Anticipate Pursuing Additional Sizable M&a Transactions This Year - Conf Call

THOMSON REUTERS
·
Aug 05

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 05

Gilead Sciences Inc Q2 Adjusted EPS USD -6.75 Vs. IBES Estimate USD -7.24

Reuters
·
Aug 05

Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger Story

Dow Jones
·
Aug 05

Gilead Q2 FY26 Loss Per Share Widens to $(8.45); Revenue Rises 10% to $7.8 Billion

Reuters
·
Aug 05

GUIDANCE: (GILD) Gilead Sciences Expects Full Year 2026 Adjusted Loss Range of $0.30 - $0.65, vs. FactSet Est of $0.75 Loss

MT Newswires Live
·
Aug 05

Gilead Second-Quarter Sales Rise 8%, Beating Wall Street Estimates

Reuters
·
Aug 05

Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate

Benzinga Earnings
·
Aug 05

Gilead: Qtrly Adj EPS $-6.75 Reflecting $-9.08 Per Share Acquired Ipr&D and Tax Expenses Associated with Recent Acquisitions

THOMSON REUTERS
·
Aug 05

Gilead Sciences Inc Q2 Product Sales USD 7,627 Million

THOMSON REUTERS
·
Aug 05

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Danaher (DHR) and Henry Schein (HSIC)

TIPRANKS
·
Aug 04